We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by Shenzhen Kangzhe Pharmaceutical Co., Ltd..
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT01489566
First Posted: December 9, 2011
Last Update Posted: December 14, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Fudan University
Medpace, Inc.
Information provided by (Responsible Party):
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: August 2013
  Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)